Xenetic Biosciences, Inc.

NasdaqCM:XBIO

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 4.29 M

Share Price

USD 2.78

Avg Daily Volume

8,263

Change (1 day)

0.36%

Change (1 year)

-30.67%

Change (YTD)

-30.33%

Xenetic Biosciences, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: -30.33%

Xenetic Biosciences, Inc. Share Price Year-To-Date (YTD) return is -30.33% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Xenetic Biosciences, Inc. 52-week low Share Price is USD 4.58 on June 20, 2025, which is 64.75% above the current Share Price.
Xenetic Biosciences, Inc. 52-week low Share Price is USD 2.30 on June 20, 2025, which is -17.27% below the current Share Price.
Xenetic Biosciences, Inc. average Share Price for the last 52 weeks is USD 3.71.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqCM: XBIO

Xenetic Biosciences, Inc.

CEO	Mr. James F. Parslow
IPO Date	June 30, 2016
Location	United States
Headquarters	40 Speen Street
Employees	2
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.